Stem Cell harvesting and storage series – Bio-Matrix Scientific Group

March 13, 2009

In our continuing series we spoke with David Koos, Chairman and CEO of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN;, an emerging San Diego, CA-based research and development biotechnology company.  BMSN opened its commercial cryogenic stem cell banking and processing facility in 2008 focusing on stem cells derived from cord blood and peripheral blood.

1. Can you tell us about Bio-Matrix and storage of stem cells for future medical need?

Bio-Matrix is a development stage biotechnology company that is focused on the cryogenic storage of adult stem cells from cord blood, peripheral blood and other tissue banking and the commercialization of medical devices used in living tissue transfer and stem cell research.

We are excited to be part of the direction of the future in Adult Stem Cell therapeutics. Stem cells lie dormant until called upon to become new cells to replace damaged ones. When transplanted, they play a large part in a wide range of medical therapies. Of the many types of stem cells, those most commonly used are blood or haematopoietic stem cells.

2. How do customers use your service?

We are offering their patients an opportunity to store their Adult Stem Cells at our banking facility for use in future regeneration medical treatments.

3. How long can cells be stored for later use?

Stem cells can be stored in cryogenic storage for over 30 years.

4. Why should families think about doing this?

Stem cell transplantations have been used either alone (e.g., for congenital diseases) or in conjunction with other treatments such as chemotherapy. Stem cells are most often used because of their ability to reconstitute cells of one or more cell lineages when administered to a patient. Most stem cell transplants use either stem cells from matched donors (allogenic) or stem cells collected from the patients (autologous) immediately before their treatment. There are number of drawbacks in allogenic transplantations, however, such as immune rejection and graft-versus-host-disease. Allogenic transplantation also is much more expensive than autologous transplantation.

The advantage of the autologous transfer methods is that is that the patient’s own cells, including stem cells, are reintroduced into the patient. The use of a patient’s own adult stem cells reduces the risk that the cells would be rejected by the immune system. Stem cells from a subject other than the patient could cause transplant rejection, and give rise to a condition called graft- versus- host disease (GVHD) in which the infused cells attack the cells of the recipient’s body. These represent a significant disadvantage, as GVHD is a difficult problem that can only be circumvented with immunosuppressive drugs.

A potential advantage of using stem cells from an adult is that the patient’s own cells could be expanded in culture and then reintroduced into the patient. Thus, there is also an unmet need in collecting human stem cell population for long term cryogenic storage and for the eventual thawing of the cryopreserved cell population for the treatment of a disease by autologous transfer.

5. Where is this service offered?

Bio-Matrix’ nearly 15,000 sq. ft. state-of-the-art facility is located in the heart of San Diego’s biotechnology corridor. This newly renovated facility, previously served as one of the American Red Cross’ national testing laboratories linking the centralized Red Cross Blood Service regions to the world’s largest blood donor database and inventory systems. This highly secured technologically advanced facility marks the initial phase of the company’s commitment to serving the present while helping to shape the future.

6. How much does it cost?

Bio-Matrix works with independent marketing companies that set their own rates. We charge based upon the number of and type of specimens being stored.

7. Other aspects of Bio-Matrix you want to mention?

Bio-Matrix’s new 15,000 sq. ft. facility, houses the company’s two secure Cryogenic Stem Cell Banks, three class 100,000 research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.

The company is aligning itself with strategic partners that offer key technologies in biomedical device development, tissue partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation.


Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of - Comments are the opinions of the individuals leaving them, and not of or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.